Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Viva Ventures Biotech Fund is a venture capital firm established in 2008, headquartered in Shanghai, China. The fund focuses on investing in first-in-class biotech companies globally, leveraging a team with over 20 years of experience in drug discovery. The firm aims to generate substantial returns by holding investments for an average of up to five years. It collaborates with top service partners and has access to leading biotech incubators and innovation centers worldwide.
The fund has a notable history of successful investments, including significant exits such as Bonti, SQZ Biotech, and Viva Biotech. The firm operates multiple funds, including Viva Ventures Biotech Fund I and II, although specific assets under management (AUM) have not been publicly disclosed. The fund's strategic positioning allows it to tap into a diverse range of biotech opportunities, particularly in the United States and Asia.
Viva Ventures Biotech Fund primarily invests in early-stage biotech companies, particularly those engaged in first-in-class drug discovery. The fund's investment strategy encompasses various stages, including pre-seed, seed, Series A, Series B, Series C, Series D, and growth equity. The firm is committed to supporting innovative therapies that address unmet medical needs, focusing on generating significant returns through strategic partnerships and a robust operational network.
The fund's geographic focus is global, with a particular emphasis on biotech companies in Asia and the United States. Viva Ventures Biotech Fund seeks to collaborate with top service partners and leverage its extensive network in drug discovery to identify promising investment opportunities. The firm values founders who demonstrate a strong vision and commitment to advancing healthcare solutions.
Viva Ventures Biotech Fund has invested in a diverse array of companies within the biotech sector. Notable portfolio companies include:
The fund has a total of 25 companies in its portfolio, showcasing its commitment to supporting early-stage biotech ventures. Notable exits from the portfolio include Bonti, which was acquired by Allergan, and SQZ Biotech, which went public. These successes highlight the fund's ability to identify and nurture high-potential biotech companies.
Dr. Han Dai: Chief Investment Officer with extensive experience in venture capital and drug discovery. Dr. Dai has a strong background in identifying and nurturing biotech innovations.
Dr. Zhixiong Ye: Chief Scientific Officer who brings a wealth of knowledge in scientific research and development. Dr. Ye has a proven track record in advancing biotech projects from concept to clinical trials.
Dr. Joanne Li: Chief Medical Officer with expertise in clinical development and regulatory affairs. Dr. Li plays a crucial role in guiding portfolio companies through the complexities of clinical trials.
Dr. Derek Ren: Executive Director and President, responsible for overseeing the fund's strategic initiatives and partnerships. Dr. Ren has a strong background in business development within the biotech sector.
To pitch to Viva Ventures Biotech Fund, founders should send their proposals via email to info@vivaventuresbiotech.com. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. The fund appreciates detailed presentations that clearly articulate the innovation and potential impact of the proposed solutions.
While specific response time expectations are not provided, founders should anticipate a thorough review process given the fund's focus on early-stage biotech investments. A warm introduction through mutual connections in the biotech community may enhance the chances of receiving a timely response.
In recent months, Viva Ventures Biotech Fund has continued to expand its portfolio, focusing on innovative biotech companies. The fund has participated in various funding rounds, supporting companies like Arthrosi Therapeutics, which is advancing its gout treatment AR882.
Additionally, the fund has been active in industry events, including the Viva Biotech 2022 Partnership Summit, which gathered leaders from the scientific research community and biopharma industry to discuss collaboration opportunities for biotech startups.
Notable exits from the portfolio include the successful IPO of SQZ Biotech and the acquisition of Bonti by Allergan, showcasing the fund's ability to identify high-potential investments.
What are the investment criteria for Viva Ventures Biotech Fund?
The fund primarily invests in early-stage biotech companies that are engaged in first-in-class drug discovery. It looks for companies that address unmet medical needs and have a strong potential for growth.
How can I pitch to Viva Ventures Biotech Fund?
Founders can reach out via email at info@vivaventuresbiotech.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes Viva Ventures Biotech Fund different from other investors?
The fund has a deep connection with Viva Biotech, a publicly listed drug discovery services company, which provides access to a robust network of incubators and service partners. This unique positioning allows the fund to de-risk projects earlier than typical venture capital firms.
What is the geographic scope of the fund's investments?
Viva Ventures Biotech Fund has a global investment strategy, with a significant focus on biotech companies in the United States and Asia. This dual focus allows the fund to tap into diverse markets and opportunities.
What is the typical check size for investments?
While specific check sizes are not disclosed, the fund participates in various stages of investment, from pre-seed to growth equity, indicating flexibility in funding amounts based on the company's needs and stage of development.
What kind of support do portfolio companies receive post-investment?
Viva Ventures Biotech Fund provides operational support and strategic guidance to its portfolio companies, leveraging its extensive network in drug discovery and access to leading incubators to help navigate the complexities of biotech development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.